source
- What’s next for GLP-1 weight loss drugs?What’s next for GLP-1 weight loss drugs? Alex Hogan explores on the new episode of STATus Report. Watch now.STAT · 1mo ago↗ source
- Antifungal from F2G, Shionogi succeeds in Phase 3 studyF2G and Shionogi released positive Phase 3 data on Thursday morning, giving the companies a potentially clear path to approval for their antifungal drug. The companies said their treatment called o…Endpoints · 1mo ago↗ source
- Kardigan extends biotech’s streak of big IPOs with $400M haulIncluding the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.BioPharma Dive · 1mo ago↗ source